Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.

被引：1
|
作者：
Sartor, A. O.
Oudard, S.
Ozguroglu, M.
Hansen, S.
Machiels, J. H.
Shen, L.
De Bono, J. S.
机构：
[1] Tulane Sch Med, New Orleans, LA USA
[2] George Pompidou European Hosp, Paris, France
[3] Istanbul Univ, Cerrahpasa Med Fac, Dept Med Oncol, Istanbul, Turkey
[4] Odense Univ Hosp, DK-5000 Odense, Denmark
[5] Catholic Univ Louvain, Ctr Canc, Clin Univ St Luc, B-1200 Brussels, Belgium
[6] Sanofi Aventis, Malvern, PA USA
[7] Inst Canc Res, Sutton, Surrey, England
[8] Royal Marsden Hosp, Sutton, Surrey, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.4525
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4525
引用
收藏
页数：1
相关论文
共 50 条
  • [21] COST EFFECTIVENESS ANALYSIS COMPARING ENZALUTAMIDE, ABIRATERONE PLUS PREDNISONE AND CABAZITAXEL PLUS PREDINSONE FOR THE TREATMENT OF VISCERAL METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) POST DOCETAXEL FAILURE
    Barqawi, Y.
    Borrego, M.
    Roberts, M.
    Abraham, I
    VALUE IN HEALTH, 2019, 22 : S75 - S75
  • [22] Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer
    Barroso-Sousa, Romualdo
    da Fonseca, Leonardo Gomes
    Souza, Karla Teixeira
    Ribeiro Chaves, Ana Carolina
    Kann, Ariel Galapo
    de Castro, Gilberto, Jr.
    Dzik, Carlos
    MEDICAL ONCOLOGY, 2015, 32 (01) : 1 - 6
  • [23] Overall survival from PANTHER: A multicenter trial of apalutamide, abiraterone acetate plus prednisone in Black and White patients with metastatic castration-resistant prostate cancer (mCRPC).
    George, Daniel J.
    Halabi, Susan
    Fleming, Mark T.
    Heath, Elisabeth I.
    Tutrone, Ronald
    Sutton, Linda
    Whang, Young E.
    Lewis, Brian E.
    Humeniuk, Michael Sandon
    Harrison, Michael Roger
    Kephart, Julie
    Hurrelbrink, Julia
    Rasmussen, Julia
    Shobe, Kellie
    Anand, Monika
    Reyes-Martinez, Marco
    Howard, Lauren
    Patierno, Steven R.
    Freedman, Jennifer A.
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer
    Romualdo Barroso-Sousa
    Leonardo Gomes da Fonseca
    Karla Teixeira Souza
    Ana Carolina Ribeiro Chaves
    Ariel Galapo Kann
    Gilberto de Castro
    Carlos Dzik
    Medical Oncology, 2015, 32
  • [25] Cabazitaxel Plus Prednisone for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel: Results from the German Compassionate-use Programme
    Heidenreich, Axel
    Scholz, Hans-Joerg
    Rogenhofer, Sebastian
    Arsov, Christian
    Retz, Margitta
    Mueller, Stefan C.
    Albers, Peter
    Gschwend, Juergen
    Wirth, Manfred
    Steiner, Ursula
    Miller, Kurt
    Heinrich, Elmar
    Trojan, Lutz
    Volkmer, Bjoern
    Honecker, Friedhelm
    Bokemeyer, Carsten
    Trojan, Lutz
    Volkmer, Bjoern
    Honecker, Friedhelm
    Bokemeyer, Carsten
    Keck, Bastian
    Otremba, Burkhard
    Ecstein-Fraisse, Evelyne
    Pfister, David
    EUROPEAN UROLOGY, 2013, 63 (06) : 977 - 982
  • [26] Phase I trial of apalutamide (Apa) with abiraterone acetate (AA) plus prednisone (P) and docetaxel (Doce) in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Nauseef, Jones T.
    Christos, Paul J.
    Thomas, Charlene
    Nordquist, Luke T.
    Sternberg, Cora N.
    Beltran, Himisha
    Guervil, Sabrina
    Galletti, Giuseppe
    Giannakakou, Paraskevi
    Nanus, David M.
    Tagawa, Scott T.
    Molina, Ana M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [27] Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients
    Buonerba, Carlo
    Federico, Piera
    D'Aniello, Carmine
    Rescigno, Pasquale
    Cavaliere, Carla
    Puglia, Livio
    Ferro, Matteo
    Altieri, Vincenzo
    Perdona, Sisto
    De Placido, Sabino
    Lorenzo, Giuseppe Di
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (06) : 1455 - 1461
  • [28] Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients
    Carlo Buonerba
    Piera Federico
    Carmine D’Aniello
    Pasquale Rescigno
    Carla Cavaliere
    Livio Puglia
    Matteo Ferro
    Vincenzo Altieri
    Sisto Perdonà
    Sabino De Placido
    Giuseppe Di Lorenzo
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 1455 - 1461
  • [29] Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
    Massard, C.
    Mateo, J.
    Loriot, Y.
    Pezaro, C.
    Albiges, L.
    Mehra, N.
    Varga, A.
    Bianchini, D.
    Ryan, C. J.
    Petrylak, D. P.
    Attard, G.
    Shen, L.
    Fizazi, K.
    de Bono, J.
    ANNALS OF ONCOLOGY, 2017, 28 (01) : 90 - 95
  • [30] A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone in docetaxel-pretreated men with metastatic castration resistant prostate cancer (mCRPC): The CABACARE trial.
    Buonerba, Carlo
    Grillone, Francesco
    Rossetti, Sabrina
    Livi, Lorenzo
    Scartozzi, Mario
    Tagliaferri, Pierosandro
    Bruzzese, Dario
    Scafuri, Luca
    Riccio, Vittorio
    Costabile, Ferdinando
    Bosso, Davide
    Iaccarino, Simona
    Facchini, Gaetano
    Carrano, Simone
    Izzo, Michela
    Caraglia, Michele
    De Placido, Sabino
    di Lorenzo, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
12345